Commentary
Article
Author(s):
In this Fall issue of CURE, we focus on AYAs with cancer, latest treatments in small cell lung cancer, preparing for a virtual visit and answering common questions about breast cancer.
Receiving a cancer diagnosis at any age is a life-altering experience, but for adolescents and young adults (AYAs) already navigating a potentially tumultuous time of life, the challenges can be amplified.
In this seasonal issue of CURE, we look at the stories of AYA patients such as Stacy Leung who, at just 23 years old, received a diagnosis of stage 2 triple-negative breast cancer. She received a second diagnosis of breast cancer 12 years later, as she was preparing for her wedding. Leung said she found empowerment in planning.
“I was at a point where I was working with a wedding event planner, I [already] got my dress and I’m like, ‘OK, this is what’s happening,’” Leung explained. “Having the unknown was the hardest part. Once I had a game plan, it was fine because I knew exactly what the moves were and what was going to happen.”
Leung’s is the latest among countless stories we have had the privilege to report on during the first 25 years of MJH Life Sciences®.
Since we started quarter century ago with a single brand, we have launched thousands of video programs, developed cutting-edge conferences and held thousands of virtual and live events, all while tirelessly covering health care news in print and online.
The driving force behind our evolution remains our passion for improving health care. We are grateful to you, our readers, for joining us on this journey.
Elsewhere in this issue, we take a deep dive into some of the latest treatment advancements for small cell lung cancer, offer insights into how best to prepare for a virtual visit with your physician and feature answers to patients’ questions on breast cancer from our Educated Patient® Summit.
Throughout these pages, you’ll find personal stories and expert insights. As always, we hope you find them inspirational and informative. Thank you for reading.
Mike Hennessy Jr.
President and CEO
MJH Life Sciences